All In Biotech

Free tool

FAERS Monitor: Zegfrovy

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219839 or its brand name (Zegfrovy, Sunvozertinib). Reports on generic versions are filed under their own applications.

Reports

41

Serious

41

100% of reports

Hospitalization

37

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea6
  • decreased appetite4
  • mouth ulceration4
  • platelet count decreased4
  • pneumonia4
  • pneumonitis4
  • toxic epidermal necrolysis4
  • chest discomfort3
  • gastric perforation3
  • oedema peripheral3
  • rash3
  • anaemia2
  • asthenia2
  • blood creatine phosphokinase increased2
  • dermatitis exfoliative2

Reports by year received

View as table
YearReports
20241
202522
202618

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,118 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
gastric perforationSignal3565.5190.11,172
dermatitis exfoliative2205.153.1228
toxic epidermal necrolysisSignal4135.253.3407
mouth ulcerationSignal497.438.4292
pneumonitisSignal475.429.7224
blood creatine phosphokinase increased235.69.237
platelet count decreasedSignal419.37.652
chest discomfortSignal315.05.127
oedema peripheralSignal312.64.222
decreased appetiteSignal48.83.521
pneumoniaSignal46.32.513
anaemia25.41.43
diarrhoeaSignal64.82.315
rash33.51.23
asthenia22.70.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.